Non-viral vector is the use of non-viral vector material physical and chemical properties to mediate gene transfer. Shenzhen Cell Valley mainly provides a unique non-viral genetic engineering technology (PiggyBac transposon modification), which is the core technology for the development of CAR T therapy. PiggyBac efficiently delivers large amounts of genetic material to T cells and can produce CAR-T products with a high percentage of dry memory cells. It includes four subtypes: single gene, single promoter double gene (IRES), double promoter double gene and double promoter double gene (WPRE).
Product advantages of this series:
① The non-viral vector has a large load and can effectively transfer large genes and a variety of AR and CR molecules;
② Low toxicity and low immune response;
③ High transfection efficiency and stable expression;
④ Higher production efficiency and lower production cost.
Shenzhen Cell Valley Biopharmaceutical Co., Ltd. is a comprehensive one-stop outsourcing service provider in China focused on the cell and gene therapy industry. It is also one of the first CRO/CDMO companies in the country to possess GMP industrial production capabilities for clinical-grade retroviral vectors . The company is a major public technical service platform construction project for CRO/CDMO in Shenzhen and is included among the city's latest announced "20+8" strategic emerging industry projects.Shenzhen Cell Valley has the capability for standardized and industrialized production of GMP-grade cell products such as CAR-T cells. Its primary production lines include those for various cell products like CAR-T, CAR-NK, CAR-M, γδT, TIL, and TCR-T. Additionally, the company operates production lines for various viral vectors, including RVV, LVV, non-viral vectors, and AAV, as well as for cellular raw materials used in producing therapeutics such as exosomes, genetically engineered antibodies, cytokines, oncolytic viruses, and vaccines.
Official WeChat Account 
.jpg "Adeno-associated virus vector")
